The strain composition of Flu-M and Flu-M Tetra for the current epidemic season fully complies with WHO recommendations.
Safety
Flu-M and Flu-M Tetra are consistent with the main global trends in the field of influenza vaccines and WHO recommendations, i.e. they are unadjuvanted inactivated split vaccines containing 15 μg of hemagglutinin per strain.
Technology
The proprietary technology used in production of Flu-M and Flu-M Tetra from strain to finished product ensures unrivalled antigen purification with the content of ovalbumin (the main allergen) in the range of 1-2 ng/dose, which is 1000 times less than in other vaccines.
After administration of Flu-M or Flu-M Tetra, human immune system recognizes the viral antigens. Despite the fact that inactivated pathogens introduced into the body cannot cause the disease, the immune system begins actively fighting against them, producing antibodies.
Some of them will bind to antigens, while others will continue circulating in the blood searching for a potential pathogen. As long as their activity is maintained, the body is protected from infection: any viral particle that enters the bloodstream will be found and “blocked”.
The immunity develops in about 2-3 weeks following the administration of Flu-M or Flu-M Tetra. From that moment on, the person is protected from the infection for at least 12 months.
The Flu-M and Flu-M Tetra production meets the GMP requirements of the Russian Federation, EAEU countries, Iran and Cuba. In addition, the production of Flu-M and Flu-M Tetra is HALAL certified.
What is the mechanism of action of the Flu-M vaccine?
After administration of Flu-M or Flu-M Tetra, human immune system recognizes the viral antigens. Despite the fact that inactivated pathogens introduced into the body cannot cause the disease, the immune system begins actively fighting against them, producing antibodies. Some of them will bind to antigens, while others will continue circulating in the blood searching for a potential pathogen. As long as their activity is maintained, the body is protected from infection: any viral particle that enters the bloodstream will be found and “blocked”.
Are there any reported changes in the vaccine efficiency against new influenza strains?
The strain composition of Flu-M and Flu-M Tetra for the current epidemic season always fully complies with WHO recommendations, which guarantees high efficiency of the vaccines against currently circulating influenza virus strains.
At what age can Flu-M or Flu-M Tetra be used for vaccination?
Flu-M is indicated for use in children aged 6 months and older, including all age groups. Flu-M is also allowed in pregnant women.
Flu-M Tetra is indicated for use in adults aged 18 years and older. An expansion of indications for the vaccine in children is currently expected.
Immunity after vaccination with Flu-M or Flu-M Tetra lasts up to 12 months.
How many vaccinations of Flu-M and Flu-M Tetra are needed?
According to the results of clinical trials, the Flu-M or Flu-M Tetra vaccination regimen is defined as a single dose.
How are Flu-M and Flu-M Tetra different from other influenza vaccines?
The Flu-M and Flu-M Tetra line of influenza vaccines contains trivalent and quadrivalent inactivated split influenza vaccines, which are consistent with the main global trends in the field of influenza vaccines and WHO recommendations, i.e. they are unadjuvanted inactivated split vaccines containing 15 μg of hemagglutinin per strain.
The proprietary strain-to-finished product production technology ensures unrivalled antigen purification with the content of ovalbumin (the main allergen) in the range of 1-2 ng/dose, which is 1000 times less than in other vaccines.
